louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06222541: Using Online Food Retail "Nudges" to Promote Healthier Beverage Intake Among Low-Income Children
Official title: Using Online Food Retail "Nudges" to Promote Healthier Beverage Intake Among Low-Income Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: Robert Wood Johnson Foundation
First posted: 2024-01-24
Enrollment: 2241
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The specific aims of this proposal are to 1) develop online food retail nudges to discourage sugary drink purchases and promote healthier substitutes; 2) examine the impact of online store nudges on purchases of sugary drinks in an online randomized controlled experiment with low-income parents, including Supplemental Nutrition Assistance Program (SNAP) and Women, Infants, and Children (WIC)-participating parents, of children age 1-5 years; and 3) disseminate findings to retailers, including those participating in the SNAP Online Purchasing Pilot.


Eligibility criteria: Inclusion Criteria:

For Aim 1, the inclusion criteria are as follows:

* parent (or caregiver) of children ages 1-5 years;
* the ability to read and write in English;
* aged 18 years or older;
* household income at or below 185% of the federal poverty level;
* previously purchased fruit drinks for their children;
* have ever shopped for groceries online in the last 12 months,
* live in the US, and
* have access to a personal computer, laptop, or tablet.

The inclusion criteria for Aim 2 are identical to the inclusion criteria for Aim 1, except the researchers will not aim to recruit exclusively parents who have previously purchased sugary drinks for their children or who have ever shopped for groceries online in the last 12 months.

Exclusion Criteria:

The exclusion criteria for Aim 1 include:

* not parent (or caregiver) of children ages 1-5 years;
* aged \<18 years or \>99 years;
* lack the ability to read and speak English;
* household income above 185% the federal poverty level;
* have never purchased fruit drinks for their children;
* have never shopped for groceries online in the last 12 months;
* do not live in the US, and;
* do not have access to a personal computer, laptop, or tablet. The exclusion criteria for Aim 2 are identical to the exclusion criteria for Aim 1, except participants who have never purchased sugary drinks for their children and have never shopped for groceries online in the last 12 months will not be excluded.

Primary outcomes:
measure: Total Calories of Sugary Drinks Purchased during Shopping Activity
timeFrame: Day 1 (Approximately 30 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Pasquale Rummo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00847041: Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.
Official title: Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Rhinosinusitis
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2009-02-19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: PROBABILITY_SAMPLE
Study population: Twenty total patients are being recruited: ten adult patients who meet the clinical criteria for chronic rhinosinusitis requiring surgical therapy and ten adult patients undergoing either orbital decompression for Graves' orbitopathy or maxillomandibular advancement for obstructive sleep apnea, with no history of sinus disease.

Brief summary: The purpose of this study is to compare the bacteria, fungi, and viruses that are present in the sinuses of patients with chronic rhinosinusitis to patients without sinus disease using a new technology, called a microarray, that will allow more accurate identification of microorganisms than current laboratory methods.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* History of chronic rhinosinusitis (CRS)
* Impaired CRS-specific quality of life
* Evidence of sinus disease on a CT scan

Exclusion Criteria:

* Control patients with any evidence of CRS by history, survey, or imaging criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05827341: A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Official title: A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Lymphoma
Clinical Trial
COVID-19
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-04-25
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Sun Yat-Sen University Cancer Center from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic. We also aimed to identify risk factors of moderate/severe COVID-19 infection and hospital admission.

Brief summary: This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,


Eligibility criteria: Inclusion Criteria:

(1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available.

Exclusion Criteria:

* Patients who could not provide detailed information about COVID-19 infection.

Primary outcomes:
measure: The severity of COVID-19
timeFrame: 2 months
measure: Hospital admission rate of COVID-19 infection
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Medical Oncology, Sun Yat-Sen University Cancer Center
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Zhiming Li
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02267941: Risk Factors for Aortic Dissection in the Chinese Patients
Official title: Food and Drug Administration in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Persistent Blood Flow in False Lumen of Aortic Dissection
Lead sponsor: General Hospital of Beijing PLA Military Region
Sponsor class: OTHER
First posted: 2014-10-20
Enrollment: 3045
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Between January, 2011 and December, 2012, we collected 3045 patients with AAD (1668 with type A and 1377 with type B) from 15 major centers in China as the case group. As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period.

Brief summary: To evaluate epidemiological features of risk factors for aortic dissection (AD) in Chinese patients.

Detailed description: Aortic dissection (AD) is a life-threatening cardiovascular disease with high mortality. Without optimal treatment, approximately 50% of patients die within one week of the onset of symptoms, and 80% die within 2 weeks. With the change of life-style and the development of diagnostic technology, the incidence and detection rate of AD were increasing in China recently. However, the cause remains unclear. Studies showed that AD were associated with some risk factors, such as hypertension, connective tissue disease, iatrogenic injury, drug, pregnancy, etc. It is reported that two thirds patients with AD had a history of hypertension; 50% patients aged \<40 years were accompanied with hereditary Marfan syndrome; 13～19% had a familial history of aortic aneurysm or dissection. These epidemiological data were obtained from Caucasian population, however, such information was not available for the Chinese population. Moreover, epidemiological investigation was absent in China, and the assessment of risk factors for AD was mainly referred to the studies from developed countries. Therefore, the aim of our study was to evaluate epidemiological features of risk factors for AD in Chinese patients using 3045 individuals from the 15 major centers in China. We anticipated that this analysis would provide helpful information preventing and controlling AD in China.

Eligibility criteria: Inclusion Criteria:

* Aortic dissection
* Acute stage

Exclusion Criteria:

-Simple aortic aneurysm and pseudoaneurysm were excluded.

Primary outcomes:
measure: Risk factor for aortic dissection in Chinese pupolation
timeFrame: Risk factor
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01458041: Iloprost Therapy in Patients With Critical Limb Ischemia
Official title: Iloprost Therapy in Patients With Critical Limb Ischemia: Evaluation of Efficacy and Safety
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Arterial Disease
Keywords: Critical limb ischaemia
Iloprost
Quality of life
Visual analogue scale
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2011-10-24
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients

Brief summary: Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.


Eligibility criteria: Inclusion Criteria:

* Patients who fulfill the internationally defined criteria of critical limb ischemia;
* Patients who are not eligible for vascular surgery or angioplasty interventions and
* Patients who are treated with iloprost infusion.
* The treating physician has decided iloprost treatment before study enrollment.

Exclusion Criteria:

* Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.

Primary outcomes:
measure: Change of limb pain at rest assessed by visual analogue scale
timeFrame: At baseline, at the end of iloprost treatment, at follow-up visits ( month 3, 6, 12)
Secondary outcomes:
measure: Incidence of ulcer healing
timeFrame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12)
measure: Collection of interventional / surgical procedures including 1) Rate of revascularization procedures; 2) Minor amputations; 3) Frequency and height of major amputations
timeFrame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12)
measure: Mortality and/or severe cardiovascular events (AMI, stroke)
timeFrame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12)
measure: Hemodynamic measurements: peripheral arterial blood flow and pressure on ankle / hallux level by Doppler scanner
timeFrame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12)
measure: Changes of transcutaneously measured tissue oxygen tension values
timeFrame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12)
Other outcomes:
Locations:
city: Many locations
country: Hungary
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05051241: A Study of GFH018 in Patients With Advanced Solid Tumors
Official title: A Phase I Study With Single/Multiple Dose Administered to Explore the Safety/Tolerability and Pharmacokinetics of GFH018 in the Treatment of Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Genfleet Therapeutics (Shanghai) Inc.
Sponsor class: INDUSTRY
First posted: 2021-09-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is the first- in human study of GFH018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration. The study is designed to explore the safety/tolerability, pharmacokinetics, and MTD of GFH018 and to define a RP2D of GFH018.


Eligibility criteria: Inclusion Criteria:

* Eligible subjects must meet all the inclusion criteria listed below:

  1. Voluntarily participate in this clinical trial and are willing to sign informed consent forms.
  2. Male or female aged from 18-75 years old (inclusive).
  3. Diagnosed with histologically or cytologically confirmed advanced solid tumors.
  4. Evaluable lesions defined by RECIST v1.1.
  5. Eastern Cooperative Oncology Group performance status of 0 to 1.
  6. Subjects or their legal representatives are able to communicate well with Investigators and are willing to comply with the protocol and complete the study.

Exclusion Criteria:

* Eligible subjects should not meet any of the exclusion criteria listed below:

  1. With clinically significant cardiac diseases.
  2. With clinically significant digestive disorders.
  3. Other severe disease.
  4. Pregnant or lactating women.
  5. Other unfavorable situations for subjects to participate in the study judged by Investigators.

Primary outcomes:
measure: Incidence of Dose-limiting Toxicity (DLT) Events
timeFrame: 31 days after the first dose
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai East hospital
Study officials:
affiliation: Leading site
name: Jin Li, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01461941: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
Official title: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Keywords: Dermatitis
Atopic
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2011-10-28
Enrollment: 78
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety profiles of E6005 ointment in patients with atopic dermatitis compared to vehicle. The pharmacokinetic profile after topical application of E6005 is also assessed.


Eligibility criteria: Inclusion Criteria

* Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained.
* Outpatients diagnosed with atopic dermatitis.

Exclusion Criteria

* Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or Netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis.
* Patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline.
* Patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.

Primary outcomes:
measure: Changes of pruritus score from baseline
timeFrame: From baseline through 12 weeks
measure: Changes of eczema area and severity from baseline
timeFrame: From baseline through 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nagoya-shi
country: Japan
state: Aichi
city: Urayasu-shi
country: Japan
state: Chiba
city: Fukuoka-shi
country: Japan
state: Fukuoka
city: Asahikawa-shi
country: Japan
state: Hokkaido
city: Sapporo-shi
country: Japan
state: Hokkaido
city: Yokohama-shi
country: Japan
state: Kanagawa
city: Adachi-ku
country: Japan
state: Tokyo
city: Chiyoda-ku
country: Japan
state: Tokyo
city: Minato-ku
country: Japan
state: Tokyo
city: Shinagawa-ku
country: Japan
state: Tokyo
Study officials:
References:
Clinical trial NCT06632041: Necrotizing Enterocolities
Official title: Haematological Disturbances in Neonates with Necrotizing Enterocolities
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Necrotizing Enterocolitis of Newborn
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-10-08
Enrollment: 70
Sex: ALL
Minimum age (years): 1
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neonates with necrotizing enterocolities

Brief summary: Haematological disturbances in neonates with necrotizing enterocolities

Detailed description: Necrotizing enterocolitis (NEC) is an acquired, multifactorial and devastating gastrointestinal disease associated with high morbidity and mortality in preterm neonates. With an incidence of about 7% in infants with BW \&lt; 1500 g and mortality up to 30%, NEC presents as a medical and surgical emergency It is characterized by ischemia, necrosis, and inflammation of bowel wall with invasion by gas-forming organisms and intramural dissection of gas ,characteristicall appearing as pneumatosis intestinalis in radiological and pathological studies. While exact etiology is undetermined, the pathogenesis is believed to be an anomalous innate immune response to an altered, less diverse intestinal microbiota by the highly immunoreactive enterocytes of premature infants, leading to inflammation and tissue necrosis

* in this devastating disease with undetermined etiology. Breast milk feeding, prolonging gestation to avoid prematurity, antenatal steroid, and the use of probiotics/prebiotics are established prevention strategies in NEC
* The hematological abnormalities associated with NEC were first described 25 years ago by Hutter et al.The abnormalities observed in a series of 40 patients with NEC included thrombocytopenia, with
* and without disseminated intravascular coagulation (DIC), neutrophilia or neutropenia, and hemolytic anemia.

Eligibility criteria: Inclusion Criteria:

* preterm less than 36 weeks
* Or very low birth weight less than 1500 gram

Exclusion Criteria:

* full term
* Normal birth weight ,Preterm with early breast feeding or more than 1500 gm

Primary outcomes:
measure: Aim
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00358241: Effects of Nerve Block on Knee Function After Knee Replacement
Official title: Effects of Continuous Lumbar Plexus Nerve Block on Functional Restoration and Outcome After Unilateral Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Postoperative Pain
Keywords: Nerve block, postoperative pain, analgesia
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2006-07-31
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Early physical therapy after knee surgery is very painful on top of pain from surgery. Pain following surgery can limit recovery. One way to treat pain is by giving intravenous (IV) pain medication with morphine. Another method is to use a "nerve block" which involves placing a thin catheter (tube) into the lower back near the nerves that sense pain in the knee and give a local anesthetic to numb the nerves. Sometimes both methods are used together. This research is being done to determine whether nerve blocks with a local anesthetic improve knee recovery in addition to providing pain relief as compared to IV pain medicine alone


Eligibility criteria: Inclusion Criteria:

* Age 21-80 year old
* ASA Physical Status ASA I and II
* Mentally competent
* Intellectually competent
* Body mass index \<35
* No severe cardiac diseases
* No severe pulmonary diseases
* Unilateral knee disease
* No other lower extremity joint disease
* No chronic narcotic therapy or illicit drug use

Exclusion Criteria:

* Age \<21 or \>80 year old
* ASA Physical Status \>ASA II
* Mentally incompetent
* Intellectually incompetent or cognitively impaired
* Non-English speaking patient
* Worker's compensation patient
* Body mass index \> 35
* Bilateral knee disease
* Has other lower extremity joint disease
* Severe cardiac diseases
* Severe pulmonary diseases
* Chronic narcotic therapy or illicit drug use
* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Bayview Medical Center
state: Maryland
Study officials:
affiliation: Johns Hopkins Medicine, Johns Hopkins University
name: J Hang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: